InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Debenture Offering
August 1, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has completed the sale of 1,240 units, with each unit consisting of one 4% senior secured $1,064 principal amount convertible debenture and 16,369 share purchase warrants. The sale, which was resulted in gross proceeds of $1,240,000 for […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Cleared for Historic Study, Begins Enrolling Participants
July 28, 2022
Company receives FDA “may proceed” letter and investigational new drug (“IND”) application clearance Enrollment for Phase 1/2a trial has already started Upcoming trial is first time a psilocybin analog will be evaluated for MDD treatment Studies show psychedelic-based treatments may have potential to revolutionize mental healthcare, but few companies have assessed limitations of oral psilocybin […]
InvestorNewsBreaks — Laredo Oil Inc. (LRDC) Announces Financial Advisory Agreement with Dawson James Securities
July 27, 2022
Laredo Oil (OTC: LRDC), an oil exploration and production company primarily engaged in acquisition and exploration efforts for mineral properties, has entered into a financial advisory agreement with Dawson James Securities. According to the announcement, Dawson will provide advice to Laredo regarding the company’s business and financial planning, corporate organization and structure, and private and […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Study Evaluating Topically Administered Ketamine Formulation
July 27, 2022
Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, has reported that its recent animal study evaluating topically administered ketamine reached a positive end point: using SILO’s selected formulation and partnered, patented delivery system, the study indicated reversal of allodynia and hyperalgesia. According to the announcements, the proprietary formulation reduced mechanical allodynia and hyperalgesia at […]
Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study
July 25, 2022
Silo Pharma produced initial batch of SPU-21 liposomes for rheumatoid arthritis study conducted by CRO Frontage Laboratories Recent company research revealed SPU-21 liposomes can target inflamed epithelium, suggesting use for targeted drug delivery SPU-21 can be used for development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis Company recently announced positive results in […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO), UMB Collaborating on Potentially Significant Homing-Peptide Technology
July 22, 2022
Silo Pharma (OTCQB: SILO) earlier this year extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and blood vessels). “Silo’s partnership with UMB focuses on peptides used for investigating and treating the arthritogenic […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Reports on First Full-Year Revenue, Issues KWC Status Update
July 21, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has released an update on its both its financial and corporate status. According to the announcement, the company released its first end-of-year earnings report in May, which showed $1.5 million annual revenue and a growth in […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Celebrates Third Recognition of Delic Labs’ Dr. Markus Roggen to Cannabis Scientist Power List
July 20, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, was named to the Cannabis Scientist Power List for the third consecutive year. Due to his commitment to creating a body of […]
Nowigence Inc. (NOWG) Starts Trading on OTC
July 18, 2022
On June 14, Nowigence emerged from being a private company to being publicly listed OTCQB Venture Market offers lower cost, complexity than a U.S. exchange listing NOWG’s AI knowledge engine mimics the way humans absorb knowledge as they search massive volumes of information In what the company CEO is calling a historic milestone, Nowigence’s (OTCQB: […]
Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs
July 13, 2022
Silo’s partnership with UMB could yield therapeutics that limit side effects through precisely targeted delivery On February 3, 2022, Silo Pharma (OTCQB: SILO) extended its research partnership with the University of Maryland, Baltimore (“UMB”) to explore potentially lifesaving joint-homing peptides that target inflamed endothelium (a thin membrane that lines the inside of the heart and […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study
July 12, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company, today announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. “The successful results of our study show that the subcutaneous route of liposomal administration is well-suited for use in targeted drug delivery of anti-arthritic […]
InvestorNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) CYB003 Phase 1/2a Clinical Trial Through Clinilabs Begins Enrollment
July 12, 2022
Clinilabs Drug Development Corporation, a global, full-service contract research organization with deep expertise in central nervous system drug development, today announced commencement of enrollment in a phase 1/2a clinical trial of CYB003. Being developed by Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” CYB003 is the […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients
July 8, 2022
Silo Pharma (OTCQB: SILO) is committed to serving patients, families and caregivers worldwide struggling with Alzheimer’s Disease (“AD”). Last year, the company entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for AD. Silo Pharma CEO Eric Weisblum expressed encouragement on partnering with Columbia University and Dr. Christine […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Launches Ketamine Wellness Integrative Therapist Directory
June 30, 2022
Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), today officially launched the Ketamine Wellness Integrative Therapist Directory. According to the update, the comprehensive resource will connect KWC patients with qualified mental health practitioners who can help them process and […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Expands IP Portfolio with New Provisional Patent Application
June 29, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of a new provisional patent for the use of psilocybin for the treatment of patients with binge eating disorder (“BED”). The new patent application is part of Tryp’s corporate strategy […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Initial Results from Feasibility Study
June 27, 2022
Study indicates that ketamine-induced changes in functional connectivity last for several days after administration of the substance Kernel Flow gathers real-time functional brain activity during clinical and research studies evaluating psychedelic-based therapeutics Technology is “precisely what we need to accelerate the development of psychedelics into therapeutics,” says Cybin CEO New data confirms Cybin’s (NEO: CYBN) (NYSE […]
Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease
June 27, 2022
In October 2021, Silo Pharma (OTCQB: SILO) entered into a sponsored research agreement (“SRA”) with Columbia University to investigate and advance psychedelic therapeutics for Alzheimer’s Disease (“AD”). SRA’s grant Silo access to world-class research facilities to sponsor potential life-changing research while offering Silo licensing opportunities for groundbreaking psychedelic remedies. Columbia University Irving Medical Center (“CUIMC”), […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Moving Forward with Phase 1/2a Clinical Trial after Receiving Key FDA Approval
June 27, 2022
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has received approval from the U.S. Food and Drug Administration (“FDA”) to proceed with its phase 1/2a first-in-human clinical trial evaluating CYB003; the company has received a “may proceed” letter and investigational new drug application (“IND”) clearance from the FDA. The approval […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Expansion of License Agreement and Patent Portfolio
June 23, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that it has expanded its commercial evaluation license agreement (“CELA”) with the University of Maryland Baltimore (“UMB”) for its next-generation liposomal peptide targeting autoimmune diseases. “We are delighted to expand our partnership with UMB. Pre-clinical testing […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Health Care and Biotech Expert as New Chief Operating Officer
June 23, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that Sid Taubenfeld, a seasoned executive with health care and biotech expertise, has joined the company’s senior leadership team as chief operating officer. “Sid brings to his new role a wealth of […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) to Present at 1st Annual H.C. Wainwright Mental Health Conference
June 23, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today confirmed details regarding Delic Corp CEO Matt Stang’s virtual attendance at the first annual H.C. Wainwright Mental Health Conference on June 27, 2022. The inaugural event will be held at the Lotte New York Palace […]
InvestorNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces First Clearance of MYCO-001 for Government-Funded Study
June 17, 2022
Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared MYCO-001 in a recent Investigational New Drug (“IND”) application, marking the first clearance of the company’s drug product. According to the update, […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs to Present at Grow Up Conference and Expo
June 16, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding Dr. Markus Roggen, president and CSO of Delic Labs, and his participation in the upcoming Grow Up Conference and Expo. During the event taking place on June 20-22, 2022, in Victoria, British […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Building on Its Holistic Approach to Mental Health Wellness
June 15, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, is devoted to finding solutions for mental ailments — not simply by easing symptoms, but by attacking the root causes of the difficulties, utilizing a toolbox of innovative, therapeutic substances. “Recently, Delic announced that six of its clinic locations will launch a specialized therapy […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research
June 13, 2022
Silo Pharma (OTCQB: SILO) still believes in medicinal mushrooms despite the fact that they are currently outlawed by the U.S. government (though legal in Oregon and decriminalized in various cities and states). Recently, the company announced that the Translational Psychedelic Research (“TrPR”) Program at the University of California San Francisco (“UCSF”) had successfully dosed [with […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Leveraging Profitable Model to Scale Best-in-Class Care Directly to Patients
June 10, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, owns and operates an assortment of related businesses and is backed by a team of industry and cannabis veterans. The company’s mission is to provide education, research, high-quality products, and effective treatment options to the masses. “In a January interview, Delic CEO and Co-Founder […]
InvestorNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Awarded Board Approval for CYB003 Phase 1/2a Clinical Trial
June 10, 2022
Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, received Institutional Review Board (“IRB”) approval to begin its planned phase 1/2a clinical trial. The trial, the first-in-human phase 1/2a trial evaluating CYBN’s proprietary deuterated psilocybin analog CYB003, is slated to begin in mid-2022.The study will evaluate CYB003 for the treatment of […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Releases Results from Phase II Binge Eating Disorder Clinical Trial
June 9, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has announced the results gathered from the first patient dosed in its phase II STOP clinical trial. According to the announcement, initial data indicates that psilocybin and psilocybin-related compounds such as Tryp’s TRP-8802 have […]
InvestorNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expanding Availability of First-of-Its-Kind Treatment – SPRAVATO(R)
June 1, 2022
Delic Holdings’ (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) subsidiary Ketamine Wellness Centers (“KWC”) , the largest ketamine therapy provider in the U.S., has expanded the availability of SPRAVATO(R) to three new cities and increased the total number of clinics offering the FDA-approved esketamine nasal spray to six. According to the update, the KWC clinics in […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Announces Completion of Annual Filings
May 31, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, has reported that, further to its news release dated May 16, 2022, the company has filed its annual financial statements, management’s discussion and analysis, and related certifications for the year ended Dec. 31, 2021, (collectively, the […]
Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties
May 31, 2022
On May 19, 2022, Silo Pharma (OTCQB: SILO) announced that The Translational Psychedelic Research (“TrPR”) Program at UCSF (University of California San Francisco) had “successfully dosed [with psilocybin] patients suffering from Parkinson’s disease.” TrPR connects researchers and medical professionals studying how psychedelics, including psilocybin, ketamine, etc., affect brain functions and other organ systems. Silo Pharma […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Completes Major Step in Advancement of CYB003 for the Treatment of Major Depressive Disorder
May 31, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics(TM),” today announced the submission of an Investigational New Drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”). According to the update, the IND is for Cybin’s phase 1/2a first-in-human clinical trial evaluating CYB003, a proprietary deuterated psilocybin analog, […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Providing Scalable, Trusted, Accessible Network of Psychedelic Clinics
May 26, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) is moving to fill the gaps exposed by substantial pandemic-induced disruptions of mental health services. This is amid the World Health Organization’s statistics that COVID-19 has led to a 25% increase in the number of cases of anxiety and depression globally. To fulfill its mission to heal the mental […]
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Efforts Boosted by New Study Indicating Effectiveness of Psychedelic Compounds
May 26, 2022
Recent study indicates psychedelic compounds show significant promise in treating a range of mental-health disorders Participants given psilocybin therapy reported a rapid, sustained improvement in their depression Cybin’s CYB003 has demonstrated less variability, faster onset, shorter duration and better brain penetration than oral psilocybin A new study sponsored by Imperial College London reports that psychedelic […]
InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Names New Independent Director to Board
May 25, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, has appointed industry leader Chris Ntoumenopoulosto its board of directors. Ntoumenopoulos has deep and impressive experience in raising capital and corporate strategy, and his expertise is well-suited to support the company’s focus on advancing […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments
May 23, 2022
Silo Pharma (OTCQB: SILO) is exploring the efficacy of ketamine in treating patients suffering from both Alzheimer’s and Parkinson’s disease. With more than 80% of Parkinson’s patients and 75% of Alzheimer’s patients experiencing dysphagia, difficulty or complete inability to swallow, last year, SILO entered into a joint venture with Zylö Therapeutics. Under the collaboration, the […]
InvestorNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Partners to Help Accelerate Regulatory Pathway of CYB003
May 23, 2022
Cybin (NYSE American: CYBN) (NEO: CYBN) is moving forward with its phase 1/2a clinical trial of its proprietary deuterated psilocybin, CYB003, which, previous research shows, has the potential to effectively treat major depressive disorder (“MDD”) with significant advantages over classic psilocybin. MDD impacts over 264 million people worldwide, 1/3 to 1/2 of whom demonstrate an […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) Announces Milestone in Psilocybin Study on Parkinson’s Patients
May 19, 2022
Silo Pharma (OTCQB: SILO), a development-stage biopharmaceutical company focused on the use of psychedelics as a therapeutic, today announced that, in conjunction with the University of California San Francisco (“UCSF”), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of the study, researchers are collecting blood samples to determine the effects of psilocybin […]
InvestorNewsBreaks – Silo Pharma Inc. (SILO) CEO Featured in Bell2Bell Podcast Episode
May 18, 2022
Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, and its founder and CEO Eric Weisblum are the center of attention in the most recent episode of the Bell2Bell Podcast. The Bell2Bell Podcast is designed to provide informative updates and exclusive interviews with executives operating in fast-moving […]
InvestorNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) CEO to Share Expansion Strategy at H.C. Wainwright Conference
May 18, 2022
Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today shared details regarding participation of its CEO Matt Stang at the H.C. Wainwright Annual Global Life Sciences Conference taking place May 23-26, 2022, in Miami, Florida. The four-day event will feature keynote presentations, investor one-on-one […]